7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
A clinical review of Vyleesi (bremelanotide) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including nausea, blood pressure changes, hyperpigmentation, and injection site reactions.
A complete timeline of Vyleesi (bremelanotide) FDA label updates from 2020 through 2026, covering safety revisions, boxed warning changes, post-market study requirements, and prescribing information modifications.
A clinical review of Vyleesi's regulatory history, patent disputes, FDA labeling restrictions, and post-market safety signals, with cited trial data and guideline references.
Complete regulatory profile of Vyleesi (bremelanotide): FDA approval history, label details, post-market safety data, and the melanocortin receptor pipeline beyond HSDD.
A complete guide to Vyleesi (bremelanotide) FDA approval, compounding legal status, prescribing label requirements, and safety data from the RECONNECT trials and post-market surveillance.
A clinical comparison of how the FDA and EMA evaluated Vyleesi (bremelanotide) for hypoactive sexual desire disorder, including approval timelines, label restrictions, safety signals, and post-market requirements.
A complete guide to bremelanotide (Vyleesi) regulatory history, FDA-approved label details, global status, and post-market safety data. prepared by the HealthRX.com Editorial Team.